Infectious Disease Control

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience , a global innovativ...

2024-10-23 15:11 1343

City microbes surviving on disinfectants, research reveals

New research shows microbes are evolving to resist cleaners used to eliminate them. It also identifies novel strains living inHong Kong that were previously only found in Antarctic desert soil. SUZHOU, China, Oct. 18, 2024 /PRNewswire/ -- After the recent pandemic, our use of disinfectants has i...

2024-10-18 17:24 2577

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...

2024-10-09 23:37 2571

New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts

Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...

2024-10-09 19:00 1109

Healgen Scientific Receives FDA De Novo Marketing Authorization for At-Home COVID-19 and Influenza Test

Healgen Rapid Check® COVID-19/Flu A&B Antigen Test was supported through the Independent Test Assessment Program (ITAP), a National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. HOUSTON, Oct. 8, 2024 /PRNewswire/ -- Healgen Scientific LLC, a leading innovator...

2024-10-08 19:00 1224

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...

2024-09-25 16:45 1798

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging

HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...

2024-09-18 16:00 1440

Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth SEATTLE, Sept. 17, 2024 /PRNewswire/ -- In its eighth annual Goalkeepers report released today, the Bill & Meli...

2024-09-17 12:01 1786

GSK shingles vaccine now available in Malaysia

A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,Shingrix (MAL24056002ARZ), ...

2024-09-13 15:07 2117

Sino Innovation Lab Partners with MASSPHOTON to Launch World-Leading Air Sterilizer, Helping to Curb the Spread of Germs

HONG KONG, Sept. 11, 2024 /PRNewswire/ -- The experience of the COVID-19 pandemic has heightened global awareness of air quality and indoor environmental safety like never before. MASSPHOTON and Sino Innovation Lab have joined forces to launch an innovative medical-grade air sterilizer aimed at ...

2024-09-11 16:32 1498

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA.  SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...

2024-09-11 14:25 1136

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays

-  Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. -  Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. -  Nature Awards to lead the application and eva...

2024-09-02 21:00 2144

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...

2024-08-28 17:29 1205

Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

-  Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay -  Designed to detect four viruses at once using multiplex PCR technology -  Utilize dual internal controls to ensure highly reliable test results -  Pledges to supply assays meeting the needs of respective countries SE...

2024-08-26 21:00 2076

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 2266

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 1982

Pfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong

* The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities inHong Kong and Macau earlier, and is available inHong Kong this month (July 2024) * Helps fight against RSV in older adults aged 60 and above and infants (throu...

2024-07-18 14:41 1848

Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore

Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the ge...

2024-07-18 13:45 1892

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 1713

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...

2024-06-07 19:00 2427
12345 ... 78

Week's Top Stories